XNASTECX
Market cap153mUSD
Jan 17, Last price
40.90USD
1D
-2.67%
1Q
9.36%
IPO
-88.91%
Name
AVROBIO Inc
Chart & Performance
P/E
12.59
P/S
—
EPS
3.25
Div Yield, %
0.00%
Shrs. gr., 5y
27.10%
Rev. gr., 5y
%
Revenues
0k
Net income
12m
P
CFO
-63m
L-35.00%
Earnings
Mar 12, 2025
Profile
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | 94,332 | 109,600 | ||||||
Unusual Expense (Income) | ||||||||
NOPBT | (94,332) | (109,600) | ||||||
NOPBT Margin | ||||||||
Operating Taxes | 377 | 157 | ||||||
Tax Rate | ||||||||
NOPAT | (94,709) | (109,757) | ||||||
Net income | 12,157 -111.46% | (106,047) -9.92% | ||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 407 | 262 | ||||||
BB yield | -0.67% | -0.84% | ||||||
| Debt | ||||||||
Debt current | 878 | 999 | ||||||
Long-term debt | 878 | 17,650 | ||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | (96,947) | (73,914) | ||||||
| Cash flow | ||||||||
Cash from operating activities | (63,190) | (97,208) | ||||||
CAPEX | (8) | (267) | ||||||
Cash from investing activities | 85,076 | (267) | ||||||
Cash from financing activities | (16,029) | 262 | ||||||
FCF | (91,190) | (109,582) | ||||||
| Balance | ||||||||
Cash | 98,303 | 92,563 | ||||||
Long term investments | 400 | |||||||
Excess cash | 98,703 | 92,563 | ||||||
Stockholders' equity | (477,271) | (489,428) | ||||||
Invested Capital | 572,888 | 582,260 | ||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 44,568 | 43,739 | ||||||
Price | 1.36 90.77% | 0.71 -81.48% | ||||||
Market cap | 60,612 94.39% | 31,182 -81.10% | ||||||
EV | (36,335) | (42,732) | ||||||
EBITDA | (93,715) | (108,160) | ||||||
EV/EBITDA | 0.39 | 0.40 | ||||||
Interest | 2,420 | 299 | ||||||
Interest/NOPBT | ||||||||